Last reviewed · How we verify
Duloxetine - low dose
Duloxetine - low dose is a Small molecule drug developed by Boehringer Ingelheim. It is currently FDA-approved.
At a glance
| Generic name | Duloxetine - low dose |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treating Negative Affect in Low Back Pain Patients (PHASE2, PHASE3)
- Multiple Ascending Dose Phase 1 Study of ALA-3000 (PHASE1)
- The Back Pain Consortium Research Program Study (PHASE4)
- A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression (PHASE2)
- The BEST Trial: Biomarkers for Evaluating Spine Treatments (PHASE4)
- Ketamine for Postherpetic Neuralgia With Depression (PHASE4)
- Duloxetine As an Analgesic in Patients Without Central Sensitivity After Same Sitting Bilateral Total Knee Arthroplasty (PHASE4)
- Medicine-induced Cardiac Hemodialysis on COVID-19 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duloxetine - low dose CI brief — competitive landscape report
- Duloxetine - low dose updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI
Frequently asked questions about Duloxetine - low dose
What is Duloxetine - low dose?
Duloxetine - low dose is a Small molecule drug developed by Boehringer Ingelheim.
Who makes Duloxetine - low dose?
Duloxetine - low dose is developed and marketed by Boehringer Ingelheim (see full Boehringer Ingelheim pipeline at /company/boehringer-ingelheim).
What development phase is Duloxetine - low dose in?
Duloxetine - low dose is FDA-approved (marketed).
Related
- Manufacturer: Boehringer Ingelheim — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing